Abstract:Senolytic drugs (Anti-aging drugs) selectively eliminate senescent cells (SC), which are resistant to apoptosis and have up-regulated anti-apoptotic pathways that protect them from their inflammatory senescence-associated secretory phenotype (SASP). These drugs temporarily disable these pathways, inducing apoptosis in SCs with a tissue-destructive SASP. Initially identified through hypothesis-driven research, senolytics like Dasatinib, Quercetin, Fisetin, and Navitoclax have shown in preclinical models to delay, prevent, or alleviate frailty, cancers, and various disorders as well as complications from organ transplantation. Senolytics like Azithromycin and Quercetin, which have anti-aging properties, are proposed as potential treatments. Since 2015, several senolytics have progressed to clinical trials. Recent studies link chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) to accelerated aging mechanisms, including cellular senescence. COPD's diversity, with its range of phenotypes, implies that lung aging may play varying roles in different phenotypes, complicating the identification of COPD patients who might benefit from senolytics. Preclinical evidence suggests senolytics reduce all-cause mortality, enhance physical function and resilience, and alleviate diseases across various organs, even in elderly patients. Diet provides energy, nutrition, and enjoyment. Studies show that major dietary components regulate aging and longevity. The potential for other dietary ingredients to prevent aging and extend longevity is intriguing. Recent findings suggest that certain plant-based ingredients can extend longevity by regulating metabolism, targeting TRP channels, reactive oxygen species (ROS), promoting mitophagy, influencing senescence pathways, and modulating circadian rhythms. Understanding these may help develop interventions for aging and related diseases. Calorie restriction and dietary manipulations that reduce ROS and inflammation while promoting autophagy can extend lifespan in model organisms. Some phytochemicals also extend lifespan in animals. This review examines the role of senescent cells in aging and disease, methods for discovering and refining senotherapeutics, and the status of senolytic preclinical and clinical trials and highlights anti-aging phytochemicals studied in cells, animals, and humans, exploring their cellular and molecular mechanisms.

Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions

Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Effect of Combined Dasatinib and Fisetin Treatment on Senescent Cell Clearance in Monkeys

The Impact of a Natural Ingredients based Intervention Targeting the Nine Hallmarks of Aging on DNA methylation

Researching New Drug Combinations with Senolytic Activity Using Senescent Human Lung Fibroblasts MRC-5 Cell Line

The effect of polyphenols on DNA methylation-assessed biological age attenuation: the DIRECT PLUS randomized controlled trial

Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age

Senolytics and Dietary Phytochemicals: Exploring Anti-Aging Strategies and Mechanisms in Aging and Disease

Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data

Examining nutrition strategies to influence DNA methylation and epigenetic clocks: a systematic review of clinical trials

DNA methylation protects cancer cells against senescence

Fisetin is a senotherapeutic that extends health and lifespan

Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial

Senolytics improve physical function and increase lifespan in old age

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

ORALLY ACTIVE, CLINICALLY TRANSLATABLE SENOLYTICS RESTORE Α-KLOTHO IN MICE AND HUMANS

Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner

Senolytic intervention improves cognition, metabolism, and adiposity in female APPNL-F/NL-F mice

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial